|Last Price||Today's Change||52-Week Range||Trading Volume|
|0.60 CAD||0.00 (0.00%)||0.55 - 1.71||22.8 thousand (Below Avg)|
Market data as of 2:43PM 11/21/14. Quotes are delayed by at least 15 min.
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer
PR Newswire - Thursday 11/20/2014 7:30 AM ET
FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen™ NDA in Adult Growth Hormone Deficiency
PR Newswire - Thursday 11/06/2014 7:00 AM ET
Aeterna Zentaris Reports Third Quarter 2014 Financial and Operating Results
PR Newswire - Tuesday 11/04/2014 4:30 PM ET
Aeterna Zentaris to Announce Third Quarter 2014 Financial and Operating Results on November 4, 2014
PR Newswire - Tuesday 10/28/2014 7:30 AM ET
Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel®
PR Newswire - Monday 10/27/2014 7:30 AM ET
|Revenue Growth (1yr)||--|
|Net Income Growth (1yr)||--|
Data is delayed by at least 15 min.